MX2020009140A - Metodos para el tratamiento de enfermedades oculares. - Google Patents

Metodos para el tratamiento de enfermedades oculares.

Info

Publication number
MX2020009140A
MX2020009140A MX2020009140A MX2020009140A MX2020009140A MX 2020009140 A MX2020009140 A MX 2020009140A MX 2020009140 A MX2020009140 A MX 2020009140A MX 2020009140 A MX2020009140 A MX 2020009140A MX 2020009140 A MX2020009140 A MX 2020009140A
Authority
MX
Mexico
Prior art keywords
methods
ocular diseases
treating ocular
treating
diseases
Prior art date
Application number
MX2020009140A
Other languages
English (en)
Inventor
Amy Racine
Andreas Weichselberger
James Warburton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2020009140A publication Critical patent/MX2020009140A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona un método para tratar a un paciente que tiene una enfermedad ocular neovascular.
MX2020009140A 2018-03-16 2019-03-08 Metodos para el tratamiento de enfermedades oculares. MX2020009140A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862643887P 2018-03-16 2018-03-16
US201962805344P 2019-02-14 2019-02-14
PCT/IB2019/051899 WO2019175727A1 (en) 2018-03-16 2019-03-08 Methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
MX2020009140A true MX2020009140A (es) 2020-09-28

Family

ID=66049363

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009140A MX2020009140A (es) 2018-03-16 2019-03-08 Metodos para el tratamiento de enfermedades oculares.

Country Status (11)

Country Link
US (1) US20210017266A1 (es)
EP (1) EP3765083A1 (es)
JP (3) JP6938796B2 (es)
KR (1) KR20200131839A (es)
CN (1) CN111867631A (es)
AU (2) AU2019235577B2 (es)
CA (1) CA3091096A1 (es)
IL (1) IL277333A (es)
MX (1) MX2020009140A (es)
TW (1) TWI727279B (es)
WO (1) WO2019175727A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150400A (en) 2006-04-07 2014-01-15 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
SI2307458T1 (en) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
PL2307457T5 (pl) 2008-06-25 2022-12-27 Novartis Ag Stabilne i rozpuszczalne przeciwciała hamujące tnf
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
SG10202109655VA (en) 2015-12-04 2021-10-28 Novartis Ag Compositions and methods for immunooncology
IL290457B1 (en) 2015-12-30 2024-10-01 Kodiak Sciences Inc Antibodies and their conjugates
MX2019011272A (es) 2017-03-22 2019-10-24 Novartis Ag Composiciones y metodos para inmunooncologia.
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
MX2021007393A (es) 2018-12-18 2021-09-23 Novartis Ag Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
HUE062928T2 (hu) 2020-03-25 2023-12-28 Ocular Therapeutix Inc Tirozin-kináz inhibitort tartalmazó szemészeti készítmény
EP4218018A1 (en) * 2020-09-23 2023-08-02 Genentech, Inc. Machine learning prediction of injection frequency in patients with macular edema

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52539B (en) 2004-10-21 2013-04-30 Genentech Inc. METHOD FOR TREATMENT OF INTRAOCULAR NEOVASCULAR DISEASES
DK3216803T3 (da) 2008-06-25 2020-06-02 Novartis Ag Stabile og opløselige antistoffer, der hæmmer vegf
KR20220097542A (ko) * 2011-01-13 2022-07-07 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
WO2014033184A1 (en) * 2012-08-28 2014-03-06 Novartis Ag Use of a vegf antagonist in treating ocular vascular proliferative diseases
TWI705827B (zh) * 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
JP6959912B2 (ja) * 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体

Also Published As

Publication number Publication date
AU2021286278C1 (en) 2024-05-23
AU2019235577B2 (en) 2021-09-30
TW201945027A (zh) 2019-12-01
US20210017266A1 (en) 2021-01-21
IL277333A (en) 2020-10-29
JP2024042697A (ja) 2024-03-28
AU2021286278A1 (en) 2022-01-20
RU2020133816A (ru) 2022-04-18
RU2020133816A3 (es) 2022-04-18
TWI727279B (zh) 2021-05-11
AU2019235577A1 (en) 2020-08-27
JP2021509912A (ja) 2021-04-08
JP6938796B2 (ja) 2021-09-22
CA3091096A1 (en) 2019-09-19
CN111867631A (zh) 2020-10-30
JP2021191778A (ja) 2021-12-16
WO2019175727A1 (en) 2019-09-19
KR20200131839A (ko) 2020-11-24
EP3765083A1 (en) 2021-01-20
AU2021286278B2 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
MX2020009140A (es) Metodos para el tratamiento de enfermedades oculares.
PH12017500843A1 (en) Methods for treating ocular diseases
IL277190A (en) Methods of treating HPV-related diseases
MX2021006901A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
EP3876712A4 (en) ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS
EP4021500A4 (en) METHOD FOR TREATING THYROID EYE DISEASE
KR102354980B9 (ko) 전안부 질환 진단 시스템 및 이를 이용한 진단 방법
ZA202103975B (en) Methods of treating disease with magl inhibitors
EP3902539A4 (en) METHOD OF TREATMENT OF PARKINSON'S DISEASE BY ADMINISTRATION OF RESINIFERATOXIN
EA202092540A1 (ru) Комбинации для лечения рака
IL290770A (en) Compounds and methods for treating oxalate-related diseases
MX2020010667A (es) Profarmacos de desoxinucleosidos para el tratamiento de enfermedades causadas por reservas desequilibradas de nucleotidos.
MX2022003101A (es) Metodos de tratamiento de enfermedades oculares.
GB202015959D0 (en) Treatment of diseases involving NAD
SG11202110659SA (en) Method for treating ocular diseases
MX2021009670A (es) Tratamiento para el cancer.
EP3840749A4 (en) METHODS OF TREATMENT OF HEART VALVE DISEASES
MX2021009413A (es) Materiales y métodos para tratar una enfermedad neurodegenerativa.
EP3917502A4 (en) METHODS OF TREATMENT OF A PATIENT WITH PARKINSON'S DISEASE
EP3755693A4 (en) AGENTS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES
EP4076656A4 (en) METHODS OF TREATMENT OF HUNTINGTON’S DISEASE
EP4058063A4 (en) METHODS OF TREATMENT OF DISEASES
BR112022008856A2 (pt) Terapia combinada para doenças musculares
HUE065591T2 (hu) Gyógyszer fertõzõ betegségek kezelésére
EP3810126A4 (en) DISEASE MODIFYING METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES USING NOOTROPIC AGENTS